Barclays initiated coverage of C4 Therapeutics (CCCC) with an Overweight rating and $8 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics: Promising Growth and Competitive Edge with TORPEDO Platform and Strategic Partnerships
- C4 Therapeutics upgraded to Overweight from Equal Weight at Stephens
- Brookline sees potential upside to outlook for C4 Therapeutics after Biogen news
- C4 Therapeutics announces Biogen had its IND for BIIB142 accepted by FDA
- C4 Therapeutics initiated with a Buy at Guggenheim